Immuneering Corporation
IMRX
$5.92
-$0.03-0.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.30M | 4.01M | 3.69M | 4.01M | 4.25M |
| Depreciation & Amortization | 7.30K | 7.30K | 7.30K | 7.30K | 7.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.76M | 15.48M | 18.56M | 15.27M | 14.91M |
| Operating Income | -14.76M | -15.48M | -18.56M | -15.27M | -14.91M |
| Income Before Tax | -14.43M | -15.05M | -18.05M | -14.60M | -14.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.43M | -15.05M | -18.05M | -14.60M | -14.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.43M | -15.05M | -18.05M | -14.60M | -14.08M |
| EBIT | -14.76M | -15.48M | -18.56M | -15.27M | -14.91M |
| EBITDA | -14.67M | -15.39M | -18.46M | -15.18M | -14.82M |
| EPS Basic | -0.40 | -0.42 | -0.58 | -0.49 | -0.47 |
| Normalized Basic EPS | -0.25 | -0.26 | -0.36 | -0.31 | -0.30 |
| EPS Diluted | -0.40 | -0.42 | -0.58 | -0.49 | -0.47 |
| Normalized Diluted EPS | -0.25 | -0.26 | -0.36 | -0.31 | -0.30 |
| Average Basic Shares Outstanding | 35.99M | 35.53M | 31.05M | 29.84M | 29.65M |
| Average Diluted Shares Outstanding | 35.99M | 35.53M | 31.05M | 29.84M | 29.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |